FibroBiologics, Inc. Common Stock (FBLG) — Cash Flow-to-Debt Ratio
FibroBiologics, Inc. Common Stock (FBLG) has a Cash Flow-to-Debt Ratio of -0.46x as of September 2025, meaning its operating cash flow of $-3.97 Million could theoretically repay 0% of its total liabilities ($8.62 Million) in one year. See FBLG FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
FibroBiologics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for FibroBiologics, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of FibroBiologics, Inc. Common Stock.
Annual Cash Flow-to-Debt Ratio for FibroBiologics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for FibroBiologics, Inc. Common Stock. Check FibroBiologics, Inc. Common Stock cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.87x | $-11.90 Million | $13.71 Million | ▼ -43.3% |
| 2024 | -0.61x | $-6.40 Million | $10.57 Million | ▼ -31.4% |
| 2023 | -0.46x | $-4.07 Million | $8.82 Million | ▲ +42.5% |
| 2022 | -0.80x | $-1.41 Million | $1.76 Million | — |